Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688262 证券简称：国芯科技 公告编号：2025-055 苏州国芯科技股份有限公司 关于收到汽车电子芯片项目中标通知书的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ●苏州国芯科技股份有限公司（以下简称"公司"）收到一家汽车整机厂商 关于供应汽车安全气囊点火驱动芯片项目的《中标通知书》，中标产品总价为 4,600万元人民币(未税)。 ●公司收到的中标通知书不构成实质性的供货合同，截至本公告披露日， 公司与客户尚未签订正式合同及交付产品，相关产品仍在进一步可靠性测试过程 中，产品的实际供货时间、供货价格、供货数量以公司与客户后续签订的正式供 货合同或销售订单及结算情况为准。公司将根据合同执行情况和收入确认政策对 项目收入进行确认。 公司于近日收到一家汽车整机厂商（限于保密要求，无法披露其名称，以下 简称"客户")的《中标通知书》，公司的汽车安全气囊点火驱动芯片中标该客户 的安全气囊项目。现将相关事项内容公告如下： 一、中标通知书概况 公司于近日收到客户的项目中标通知书，中标产品为公司的汽车安全 ...

Core Viewpoint - The company has received a bid notification for the supply of automotive airbag ignition driver chips, with a total project value of 46 million RMB (before tax), indicating strong recognition of its R&D capabilities, product quality, and supply chain capabilities [1] Group 1 - The total project value for the automotive airbag ignition driver chips is 46 million RMB (before tax) [1] - The bid reflects the client's full recognition of the company's R&D capabilities and product quality [1] - This win is expected to enhance the company's competitiveness and brand image in the automotive electronic chip market [1]

苏州国芯科技股份有限公司 证券代码：688262 证券简称：国芯科技 公告编号：2025-054 关于自愿披露公司面向下一代 48V 电子电气架构研发的汽 车电子安全气囊点火芯片新产品内部测试成功的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州国芯科技股份有限公司（以下简称"公司"）研发的面向下一代48V电 子电气架构的汽车电子安全气囊点火芯片新产品"CCL1800B"于近日在公司内部 测试中获得成功。现将相关事项内容公告如下： 一、新产品的基本情况 公司本次新产品CCL1800B是业界首次公开发布成功研发的面向汽车电子48V 电子电气架构的安全气囊点火芯片。该芯片新产品在开发过程中与头部主机厂客 户进行了充分的需求征询和方案论证，截至目前为止尚未见业界其他同类相关产 品报道。 新能源汽车智能化正驱动汽车电气化的加速发展，智能化和电气化成为驱动 汽车产业升级的核心引擎，以智能化为核心的功能创新导致低压电源系统已从单 纯的能量分配网络，演进为支撑整车智能化的中枢系统；域控架构的快速迭代、 线控底盘以及日新月异的智 ...

Group 1 - The core viewpoint of the news is that Suzhou Guoxin Technology Co., Ltd. has applied for a patent related to a PCIe cryptographic card and its communication methods, which aims to enhance security against quantum attacks [1] - The patent application was filed on April 2025, and the public announcement number is CN120223309A [1] - The technology involves a main PCIe chip device that includes a first PCIe endpoint port, a security algorithm engine, and a PCIe root complex port, designed to improve the reliability and security of cryptographic operations [1] Group 2 - Suzhou Guoxin Technology Co., Ltd. was established in 2001 and is primarily engaged in software and information technology services [2] - The company has a registered capital of approximately 335.99 million RMB [2] - The company has invested in 21 enterprises and participated in 53 bidding projects, holding 256 patents and 2 trademark registrations [2]

证券代码：688262 证券简称：国芯科技 公告编号：2025-053 苏州国芯科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为71,649,273股。 ? 本次股票上市流通日期为2025 年 7 月 7 日。（因 2025 年 7 月 6 日为非交 易日，故顺延至下一交易日） 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意苏州国芯 科技股份有限公司首次公开发行股票注册的批复》 （证监许可20213860 号）核准， 苏州国芯科技股份有限公司（以下简称"公司"、 "国芯科技"或"发行人"）首次 向社会公众公开发行人民币普通股（A 股）股票 60,000,000 股，并于 2022 年 1 月 其中有限售条件流通股合计 186,743,902 股，无限售条件流通股合计 53,256,098 股。 本次上市流通的限售股为公司首次公开发行的部分限售股 ...

首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688262 证券简称：国芯科技 公告编号：2025-053 苏州国芯科技股份有限公司 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 71,649,273股。 本次股票上市流通总数为71,649,273股。 本次股票上市流通日期为2025 年 7 月 7 日。（因 2025 年 7 月 6 日为非交 易日，故顺延至下一交易日） 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意苏州国芯 科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]3860 号）核准， 苏州国芯科技股份有限公司（以下简称"公司"、"国芯科技"或"发行人"）首次 向社会公众公开发行人民币普通股（A 股）股票 60,000,000 股，并于 2022 年 1 月 6 日在上海证券交易所挂牌上市。公司首次公开发行后总股本为 240,000,000 股， 其中有限售 ...

首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为苏 州国芯科技股份有限公司（以下简称"国芯科技"或"公司"）持续督导的保荐 人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 相关法律、法规和规范性文件的规定，对国芯科技首次公开发行部分限售股上 市流通的事项进行了专项核查，核查情况与意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2021 年 12月 7日出具的《关于同意苏州国芯 科技股份有限公司首次公开发行股票注册的批复》（证监许可[2021]3860 号）核 准，苏州国芯科技股份有限公司（以下简称"公司"、"国芯科技"或"发行人"） 首次向社会公众公开发行人民币普通股（A 股）股票 60,000,000 股，并于 2022 年 1 月 6 日在上海证券交易所挂牌上市。公司首次公开发行后总股本为 240,000,000 股，其中有限售条件流通股合计 186,743,902 股，无限售条件流通股 合计 53,256,098 股。 本次上 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688262 证券简称：国芯科技 公告编号：2025-052 苏州国芯科技股份有限公司 （依法须经批准的项目，经相关部门批准后方可开展经营活动）一般项目： 非居住房地产租赁；物业管理（除依法须经批准的项目外，凭营业执照依法自主 开展经营活动） 法定代表人：郑茳 注册资本：33,599.9913 万元整 成立日期：2001 年 06 月 25 日 住所：苏州市高新区汾湖路 99 号狮山总部经济中心 1 号楼 经营范围：微电子技术与产品的设计、开发、生产；集成电路工程技术培训； 软件工程及技术服务；经营本企业自产产品及技术的出口业务；经营本企业生产、 科研所需的原辅材料、仪器仪表、机械设备、零配件及技术的进口业务（国家限 定公司经营和国家禁止进出口的商品及技术除外）；经营进料加工和"三来一补" 业务。 苏州国芯科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开 第二届董事会第二十七次会议及第二届监事会第二十六次会议，审议通过了《关 于取消监事会、 ...

苏州国芯科技股份有限公司 章程 中国·苏州 目 录 苏州国芯科技股份有限公司 章程 第一章 总则 第一条 为维护苏州国芯科技股份有限公司（以下简称"公司"）、股东、职 工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 和其他有关规定，制订《苏州国芯科技股份有限公司章程》（以下简称"本章程"）。 第二条 公司系依照《公司法》和其他有关规定由苏州国芯科技有限公司整体 变更设立的股份有限公司。公司在苏州市行政审批局注册登记，取得统一社会信用 代码为 91320505729311356W 的《营业执照》。 第三条 公司于 2021 年 6 月 25 日经上海证券交易所审核同意、于 2021 年 12 月 7 日经中国证券监督管理委员会（以下简称"中国证监会"）同意注册，首次向 社会公众发行人民币普通股 6,000 万股，并于 2022 年 1 月 6 日在上海证券交易所科 创板上市。 第四条 公司注册中文名称：苏州国芯科技股份有限公司 英文名称：SUZHOU C*Core Technology Co., Ltd. ...